FERUMOXTRAN 10
Cervical Adenocarcinoma
National Cancer Institute (NCI)OtherPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 34/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Cervical Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Uganda Cancer Institute | Phase 2 | BB |
e7 tcr-t cells Christian Hinrichs | Phase 2 | B |
PEGFILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Veliparib National Cancer Institute (NCI) | Phase 2 | B |
View all 21 →
Same molecule, other indications
FERUMOXTRAN 10 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →